

Supplementary Online Content

Myhre PL, Vaduganathan M, Claggett BL, et al. Association of natriuretic peptides with cardiovascular prognosis in heart failure with preserved ejection fraction: secondary analysis of the TOPCAT randomized clinical trial. *JAMA Cardiol*. Published online August 22, 2018. doi:10.1001/jamacardio.2018.2568

eTable. Baseline characteristics of patients in TOPCAT Americas (n=1,767) in patients with and without available natriuretic peptide levels.

eFigure 1. Distribution of log-transformed, standardized natriuretic peptide (NP) levels by enrollment strata in TOPCAT Americas.

eFigure 2. Baseline natriuretic peptides in 6 subgroups of the hospitalization strata of TOPCAT Americas (n=370).

eFigure 3. Baseline natriuretic peptides in 5 subgroups of TOPCAT Russia and Georgia (n=366).

This supplementary material has been provided by the authors to give readers additional information about their work.


eTable. Baseline characteristics of patients in TOPCAT Americas (n=1,767) in patients with and without available natriuretic peptide levels.

	Available NP Levels (n=1,057, 60%)		Missing NP Levels (n=710, 40%)		P
Randomization to Spironolactone	535	(50.6%)	351	(49.4%)	0.63
Eligibility Criteria					<0.001
Prior HF Hospitalization in 12mo	370	(35.0%)	606	(85.4%)	
Elevated NP in 60 days	687	(65.0%)	104	(14.6%)	
Age (years)	72.3 ± 9.8		70.5 ± 9.6		<0.001
Male	514	(48.6%)	368	(51.8%)	0.19
Black	183	(17.3%)	119	(16.8%)	0.76
Left Ventricular Ejection Fraction (%)	58.2 ± 7.4		58.1 ± 8.2		0.90
New York Heart Association Class III or IV	386	(36.7%)	234	(33.0%)	0.12
Hypertension	952	(90.2%)	636	(89.7%)	0.76
Diabetes Mellitus	464	(43.9%)	324	(45.7%)	0.47
eGFR<60 mL/min/1.73 m²	554	(52.4%)	358	(50.4%)	0.41
Previous Myocardial Infarction	217	(20.5%)	142	(20.0%)	0.79
Previous Cerebrovascular Accident	101	(9.6 %)	57	(8.0 %)	0.27
Peripheral Artery Disease	128	(12.1%)	79	(11.1%)	0.53
History of Atrial Fibrillation	472	(44.7%)	271	(38.2%)	0.007
Atrial Fibrillation on ECG at inclusion	289	(35.0%)	157	(31.2%)	0.15
Chronic Obstructive Pulmonary Disease	178	(16.9%)	113	(15.9%)	0.61
Body Mass Index (kg/m²)	33.4 ± 8.5		34.7 ± 8.2		0.002
Systolic Blood Pressure (mmHg)	127.1 ± 15.8		128.1 ± 16.0		0.19
Heart Rate (bpm)	68.5 ± 11.0		69.9 ± 11.6		0.008
Baseline Medication Use					
β-blocker	852	(80.6%)	535	(75.6%)	0.01
Calcium Channel Blocker	414	(39.2%)	268	(37.9%)	0.58
Diuretic	937	(88.6%)	636	(89.8%)	0.43
ACEi/ARB	816	(77.2%)	579	(81.8%)	0.02
Statin	618	(58.5%)	409	(57.8%)	0.77
Aspirin	852	(80.6%)	535	(75.6%)	0.01


Data reported as n (%) or mean ± standard deviation

Abbreviations: ACEi/ARB = angiotensin-converting enzyme inhibitor / angiotensin II receptor blocker; ECG = electrocardiogram; eGFR = estimated glomerular filtration rate; HF=heart failure; NP = natriuretic peptide.

eFigure 1. Distribution of log-transformed, standardized natriuretic peptide (NP) levels by enrollment strata in TOPCAT Americas.



eFigure 2. Baseline natriuretic peptides in 6 subgroups of the hospitalization strata of TOPCAT Americas (n=370).



eFigure 3. Baseline natriuretic peptides in 5 subgroups of TOPCAT Russia and Georgia (n=366).

